Ani Pharmaceuticals (ANIP) Debt to Equity (2019 - 2023)

Ani Pharmaceuticals (ANIP) has 5 years of Debt to Equity data on file, last reported at $0.84 in Q1 2023.

• For the quarter ending Q1 2023, Debt to Equity rose 1.65% year-over-year to $0.84; the trailing twelve-month figure through Mar 2023 stood at $0.84 (up 1.65% YoY), and the FY2022 full-year result was $0.84, up 5.34% from the prior year.
• Debt to Equity steadied at $0.84 in Q1 2023, from $0.84 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $1.07 in Q2 2021 to a low of $0.8 in Q4 2021.
• A 5-year average of $0.9 and a median of $0.85 in 2022 frame the typical range for Debt to Equity.
• Across the five-year window, Debt to Equity advanced 8.7% in 2020 and dropped 20.16% in 2022, its largest moves.
• Tracing ANIP's Debt to Equity over 5 years: stood at $0.87 in 2019, then climbed by 8.7% to $0.95 in 2020, then decreased by 15.57% to $0.8 in 2021, then advanced by 5.34% to $0.84 in 2022, then retreated by 0.06% to $0.84 in 2023.
• Business Quant data shows ANIP's Debt to Equity at $0.84 in Q1 2023, $0.84 in Q4 2022, and $0.85 in Q3 2022.